Paediatric oncology in the Eastern Mediterranean region (EMR): the current state and challenges

Arsalan Kabir Siddiqui1, Asim Fakhruddin Belgaumi1,2

  • 1All authors have contributed to this manuscript and take responsibility for its contents.

Ecancermedicalscience
|March 5, 2024
PubMed

Insights

Childhood cancer care varies greatly across the WHO Eastern Mediterranean Region due to economic diversity. Regional collaboration and initiatives show promise for improving equitable access to quality pediatric oncology services.

Area of Science:

  • Global Health
  • Pediatric Oncology
  • Health Systems Research

Background:

  • The WHO Eastern Mediterranean Region (EMR) exhibits significant economic diversity, impacting healthcare system development and childhood cancer care provision.
  • Paediatric oncology care ranges from highly sophisticated services in some nations to non-existent provision in others within the EMR.
  • The reported age-standardised incidence rate of childhood cancer (10.1 per 100,000) may be underestimated due to potential under-registration.

Purpose of the Study:

  • To assess the current state of childhood cancer care in the WHO Eastern Mediterranean Region.
  • To identify challenges and opportunities for improving paediatric oncology services and equitable access.
  • To highlight the potential for regional collaboration and existing initiatives in enhancing cancer care capacity.

Main Methods:

  • A review of healthcare systems and childhood cancer care provision across diverse economic settings in the EMR.
  • Analysis of factors influencing care capacity, including provider training, infrastructure, and financial accessibility.
  • Examination of the impact of geopolitical instability and natural disasters on healthcare services.

Main Results:

  • Significant disparities in paediatric oncology care capacity and access exist across the EMR, influenced by country income levels.
  • Shortages of trained healthcare providers are prevalent, particularly in low and lower-middle-income countries, though training programs are emerging.
  • High out-of-pocket expenditures (up to 75%) burden families in lower-income nations, with charitable foundations and public hospitals providing some support.
  • Geopolitical turmoil and natural disasters have adversely affected healthcare capacity in several regional countries.

Conclusions:

  • Substantial inequities in childhood cancer care persist within the EMR, necessitating targeted interventions.
  • Regional collaboration, educational support, and twinning programs offer a viable strategy for capacity building and infrastructure improvement.
  • Despite challenges, positive change is evident, driven by initiatives like the WHO Global Initiative for Childhood Cancer, indicating an upward trajectory for care improvement.

Related Concept Videos

Cancer Survival Analysis01:21

Cancer Survival Analysis

Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
345
Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
7.7K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.6K